Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes.
Latest Information Update: 22 May 2024
At a glance
- Drugs Decitabine (Primary) ; Tretinoin (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 09 May 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 09 May 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.